Thursday, September 8, 2011
ISTA Pharmaceuticals Inc., of Irvine, Calif., said a paper published in RETINA, The Journal of Retinal and Vitreous Diseases, of a pilot study suggested that the topical nonsteroidal anti-inflammatory eye drop Xibrom (bromfenac ophthalmic solution) administered twice daily might have an additive effect when used with intravitreal Lucentis (ranibizumab injection, Roche AG) in reducing retinal thickness in neovascular age-related macular degeneration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.